Hikma Pharmaceuticals (CHIX:HIKL) Change In Other Working Capital: £0 Mil (TTM As of Dec. 2025)


CHIX:HIKL Hikma Pharmaceuticals PLC CHIX:HIKL
80 GF Score
Price £15.11
GF Value £20.99
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Change In Other Working Capital?

Hikma Pharmaceuticals CHIX:HIKL +1.96% 80 Change In Other Working Capital is £0 Mil as of Dec. 2025. GuruFocus rates CHIX:HIKL with a GF Score™ of 80/100 and a GF Value™ of £20.99 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Hikma Pharmaceuticals's Change In Other Working Capital for the quarter that ended in Dec. 2025 was £0 Mil. It means Hikma Pharmaceuticals's Other Working Capital stayed the same from Jun. 2025 to Dec. 2025 .

Hikma Pharmaceuticals's Change In Other Working Capital for the fiscal year that ended in Dec. 2025 was £-51 Mil. It means Hikma Pharmaceuticals's Other Working Capital declined by £51 Mil from Dec. 2024 to Dec. 2025 .

Hikma Pharmaceuticals Change In Other Working Capital Historical Data

* Premium members only.

The historical data trend for Hikma Pharmaceuticals's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hikma Pharmaceuticals Change In Other Working Capital Chart

Hikma Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75.20 -27.09 173.01 95.71 -50.80

Hikma Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 136.67 -40.09 136.05 0.00 0.00
CHIX:HIKL
80GF Score
Hikma Pharmaceuticals PLC CHIX:HIKL
Change In Other Working Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Change In Other Working Capital of £0 Mil mean?
Hikma Pharmaceuticals (CHIX:HIKL) has a Change In Other Working Capital of £0 Mil as of Dec. 2025. Change In Other Working Capital is any increase or decrease between periods of other working capital. View historical data on Hikma Pharmaceuticals and its competitors.
Is Hikma Pharmaceuticals' Change In Other Working Capital too high?
Hikma Pharmaceuticals' current Change In Other Working Capital is £0 Mil. Overall, Hikma Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Change In Other Working Capital compare to ZTS and UTHR?
Hikma Pharmaceuticals' Change In Other Working Capital of £0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Other Working Capital for a Drug Manufacturers company?
A good Change In Other Working Capital depends on the Drug Manufacturers industry context. However, Change In Other Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Other Working Capital mean?
A high Change In Other Working Capital can signal that a stock is expensive relative to its fundamentals. Change In Other Working Capital is any increase or decrease between periods of other working capital. View historical data on Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current Change In Other Working Capital is £0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (CHIX:HIKL) is currently considered Modestly Undervalued. The stock's GF Value™ is £20.99, compared to a current price of £15.11 — trading 28% below its estimated fair value. The current Change In Other Working Capital is £0 Mil. Hikma Pharmaceuticals' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Other Working Capital calculated?
Change In Other Working Capital is calculated from a company's financial statements. For Hikma Pharmaceuticals (CHIX:HIKL), the current Change In Other Working Capital is £0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (CHIX:HIKL) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of £15.11 is trading 28% below its estimated GF Value™ of £20.99. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for CHIX:HIKL:

  • Change In Other Working Capital: £0 Mil
  • GF Value™: £20.99 vs. price of £15.11 (28% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the CHIX:HIKL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
80GF Score

Get the complete analysis for CHIX:HIKL

Change In Other Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£15.11
Price
£20.99
GF Value